Capnography Presentation Wins First Place at Annual Conference in Spain

Jerusalem/Needham -- June 29, 2009 -- Oridion Systems Ltd. (SIX Swiss Exchange: ORIDN) today announced that a medical research presentation using Capnography (the non-invasive monitoring of CO2) conducted during Cardiopulmonary Resuscitation (CPR) was awarded first place during the 21st Spanish Society of Emergency Medicine (SEMES) Conference held in Benidorm, Spain from June 3-6. The study showed that capnography can improve patient safety during pre-hospital CPR.

The presentation, "Capnography during CPR in SUMMA 112: Preliminary Study" focused on an analysis conducted at Madrid's Emergency Medical Service by a research group headed by LD Diez-Picazo, MD. Using Lifepak12 defibrillators (Physio Control) equipped with Oridion capnography modules, the study analyzed the effectiveness of CPR as indicated by capnography monitoring. The study was completed by an emergency unit of SUMMA 112 between January 2008 and February 2009. Advanced CPR was conducted on these patients, based on the European Resuscitation Council (ERC) Guidelines for Resuscitation 2005, which recommends using capnography during CPR to verify endotracheal tube (ETT) position.

The researchers concluded that capnography monitoring during pre-hospital cardiac arrest confirms ETT placement, assessment of the quality of chest compressions, is an early alert of return of spontaneous circulation (ROSC) and prognostic value determining the outcome (ROSC vs. death).

This study joins others in confirming the significance of monitoring the carbon dioxide (CO2) in a patient's exhaled breath for the enhancement of patient safety. As in many other clinical environments, capnography monitoring in the pre-hospital setting serves as a powerful tool in assessing a patient's ventilatory status.

The Spanish Society of Emergency Medicine (SEMES) is one of the oldest European Societies in Emergency Medicine. SEMES is a member of the European Federation of National Societies at the European Emergency Medicine Society and the largest National Society with approximately 10,000 members (doctors, nurses and technicians).

For further information please contact:
Alan Adler, Chairman and Chief Executive Officer
Walter Tabachnik, Chief Financial Officer
Elena Gerberg, Investor Relations
e-mail investor@oridion.com
website www.oridion.com
phone +972 2 589 9159
address Oridion Systems Ltd., P.O. Box 45025, 91450 Jerusalem, Israel

About Oridion
Oridion Systems Ltd. (www.oridion.com) is a global medical device company specializing in patient safety monitoring. The Company operates through wholly owned subsidiaries in the United States, Europe, and Israel.

Oridion develops proprietary medical devices and patient interfaces, based on its patented Microstream® technologies, for the enhancement of patient safety through the monitoring of the carbon dioxide (CO2) in a patient's breath. These products provide effective, proven airway management and are used in various clinical environments, including procedural sedation, pain management, operating rooms, critical care units, post-anesthesia care units, emergency medical services, transport, alternate care and other settings where patients' ventilation may be compromised and at risk.

Certain statements made herein that are not historical are forward-looking. The words "estimate" "project" "intend" "expect" "believe" and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among others, our ability to maintain profits, the market demands for our Capnography products, our ability to focus our team on the Capnography business, changes in general economic and business conditions, inability to maintain market acceptance to the Company's products, inability to timely develop and introduce new technologies, products and applications, rapid changes in the market for the Company's products, loss of market share and pressure on prices resulting from competition, introduction of competing products by other companies, inability to manage growth and expansion, loss of key OEM partners, inability to attract and retain qualified personnel, inability to protect the Company's proprietary technology.